Cognition After Lowering LDL-Cholesterol With Evolocumab
ContributorsGencer, Baris; Mach, François; Guo, Jianping; Im, KyungAh; Ruzza, Andrea; Wang, Huei; Kurtz, Christopher E; Pedersen, Terje Rolf; Keech, Anthony C; Ott, Brian R; Sabatine, Marc S; Giugliano, Robert P; FOURIER Investigators
Published inJournal of the American College of Cardiology, vol. 75, no. 18, p. 2283-2293
Publication date2020-05-12
Abstract
Keywords
- PCSK9 inhibitor
- Cholesterol
- Cognition
- Lipid-lowering therapies
- Safety
- Statin
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized / administration & dosage
- Antibodies, Monoclonal, Humanized / adverse effects
- Anticholesteremic Agents / administration & dosage
- Anticholesteremic Agents / adverse effects
- Atherosclerosis / blood
- Atherosclerosis / drug therapy
- Atherosclerosis / psychology
- Cardiovascular Diseases / blood
- Cardiovascular Diseases / drug therapy
- Cardiovascular Diseases / psychology
- Cholesterol, LDL / antagonists & inhibitors
- Cholesterol, LDL / blood
- Cognition / drug effects
- Cognition / physiology
- Cognitive Dysfunction / blood
- Cognitive Dysfunction / chemically induced
- Cognitive Dysfunction / psychology
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
- Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
- Male
- Middle Aged
Affiliation
Research group
Citation (ISO format)
GENCER, Baris et al. Cognition After Lowering LDL-Cholesterol With Evolocumab. In: Journal of the American College of Cardiology, 2020, vol. 75, n° 18, p. 2283–2293. doi: 10.1016/j.jacc.2020.03.039
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:163627
- DOI : 10.1016/j.jacc.2020.03.039
- PMID : 32381158
ISSN of the journal0735-1097